DK2007362T3 - Orale doseringsformer, herunder et antitrombocytmiddel og en syrehæmmer - Google Patents

Orale doseringsformer, herunder et antitrombocytmiddel og en syrehæmmer Download PDF

Info

Publication number
DK2007362T3
DK2007362T3 DK07760105.2T DK07760105T DK2007362T3 DK 2007362 T3 DK2007362 T3 DK 2007362T3 DK 07760105 T DK07760105 T DK 07760105T DK 2007362 T3 DK2007362 T3 DK 2007362T3
Authority
DK
Denmark
Prior art keywords
dosage form
oral dosage
clopidogrel
omeprazole
effective amount
Prior art date
Application number
DK07760105.2T
Other languages
English (en)
Inventor
Mark A Goldsmith
Elizabeth Vadas
Original Assignee
Kg Acquisition Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kg Acquisition Llc filed Critical Kg Acquisition Llc
Application granted granted Critical
Publication of DK2007362T3 publication Critical patent/DK2007362T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Claims (12)

1. Anvendelse af en adenosindiphosphat (ADP)-antagonist eller P2Yi2-anta-gonist og en protonpumpehæmmer (PPI) til fremstilling af en farmaceutisk sammensætning til behandling af en patient med en gastrointestinal (GI) sygdom forbundet med en ADP- eller P2Yi2-antagonist hos en patient, hvor patienten ikke vides at have en GI sygdom, hvor den farmaceutiske sammensætning er en oral enkeltenhedsdoseringsform, der omfatter: (a) en terapeutisk virksom mængde af en adenosindiphosphat (ADP)-antago-nist eller P2Yi2-antagonist til hæmning af trombocytaggregation, hvor ADP- eller P2Yi2-antagonisten er clopidogrel eller et farmaceutisk acceptabelt salt, solvat, hydrat, enantiomer eller polymorf deraf; og (b) en terapeutisk virksom mængde af en PPI til forebyggelse af en GI sygdom forbundet med ADP- eller P2Yi2-antagonisten, hvor PPI'en er omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf; hvor PPI'en er enterisk coatet; og hvor den orale enkeltenhedsdoseringsform ikke indbefatter et ikke-aspirin ikke-steroidt anti-inflammatorisk lægemiddel (NSAID).
2. Anvendelse ifølge krav 1, hvor enhedsdoseringsformen omfatter ca. 20-200 mg clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf.
3. Anvendelse ifølge krav 1 eller 2, hvor enhedsdoseringsformen omfatter ca. 10-100 mg omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf.
4. Anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor enhedsdoseringsformen omfatter: (a) 50-100 mg clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf; og/eller (b) 10-40 mg omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf.
5. Anvendelse ifølge krav 1, hvor enhedsdoseringsformen omfatter ca. 75 mg clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf.
6. Anvendelse ifølge krav 1,2,4 eller 5, hvor enhedsdoseringsformen omfatter ca. 20 mg omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf.
7. Oral enkeltenhedsdoseringsform, der omfatter en terapeutisk virksom mængde af en adenosindiphosphat (ADP)-antagonist eller P2Yi2-antagonist og en terapeutisk virksom mængde af en protonpumpehæmmer (PPI), hvor ADP- eller P2Yi2-antagonisten er clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf, og PPI'en er omeprazol eller et farmaceutisk acceptabelt salt, ester, solvat, polymorf, hydrat eller enantiomer deraf, hvor PPI'en er enterisk coatet; og hvor doseringsformen er uden et ikke-steroidt anti-inflammatorisk lægemiddel (NSAID).
8. Doseringsform ifølge krav 7, hvor enhedsdoseringsformen omfatter ca. 20-200 mg clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf.
9. Doseringsform ifølge 7 eller 8, hvor enhedsdoseringsformen omfatter ca. 10-100 mg omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf.
10. Doseringsform ifølge et hvilket som helst af kravene 7 til 9, hvor enhedsdoseringsformen omfatter: (a) 50-100 mg clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf; og/eller (b) 10-40 mg omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf.
11. Doseringsform ifølge krav 7, hvor enhedsdoseringsformen omfatter ca. 75 mg clopidogrel eller et farmaceutisk acceptabelt salt, solvat, polymorf, hydrat eller enantiomer deraf.
12. Doseringsform ifølge krav 7, 8, 10 eller 11, hvor enhedsdoseringsformen omfatter ca. 20 mg omeprazol eller et farmaceutisk acceptabelt salt, enantiomer eller polymorf deraf.
DK07760105.2T 2006-04-04 2007-04-04 Orale doseringsformer, herunder et antitrombocytmiddel og en syrehæmmer DK2007362T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78954306P 2006-04-04 2006-04-04
US81232606P 2006-06-09 2006-06-09
PCT/US2007/065967 WO2007115305A2 (en) 2006-04-04 2007-04-04 Oral dosage forms including an antiplatelet agent and an acid inhibitor

Publications (1)

Publication Number Publication Date
DK2007362T3 true DK2007362T3 (da) 2018-11-26

Family

ID=38564311

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07760105.2T DK2007362T3 (da) 2006-04-04 2007-04-04 Orale doseringsformer, herunder et antitrombocytmiddel og en syrehæmmer

Country Status (24)

Country Link
US (1) US9504678B2 (da)
EP (1) EP2007362B1 (da)
JP (3) JP5844028B2 (da)
KR (2) KR20150105419A (da)
CN (1) CN101460154B (da)
AU (1) AU2007234398B9 (da)
BR (1) BRPI0709745A2 (da)
CA (1) CA2647497C (da)
CY (1) CY1120961T1 (da)
DK (1) DK2007362T3 (da)
ES (1) ES2699444T3 (da)
HK (1) HK1131566A1 (da)
HR (1) HRP20181971T1 (da)
HU (1) HUE040311T2 (da)
IL (1) IL194472A (da)
LT (1) LT2007362T (da)
MX (2) MX2008012514A (da)
PL (1) PL2007362T3 (da)
PT (1) PT2007362T (da)
RS (1) RS58162B1 (da)
SG (1) SG170826A1 (da)
SI (1) SI2007362T1 (da)
TR (1) TR201816133T4 (da)
WO (1) WO2007115305A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007214474B2 (en) * 2006-02-17 2011-01-20 Novartis Ag Disintegrable oral films
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
MX2008012514A (es) 2006-04-04 2009-02-10 Cogentus Pharmaceuticals Inc Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de acido.
HU230261B1 (hu) * 2007-11-27 2015-11-30 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás gyógyszeripari intermedierek előállítására
WO2009118763A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Multilayered pharmaceutical compositions and processes thereof
CN101554378B (zh) * 2008-04-09 2011-01-12 鲁南制药集团股份有限公司 含有普拉格雷的药物组合物
FR2932387B1 (fr) * 2008-06-16 2010-09-17 Cll Pharma Composition orale contenant un agent anti-plaquettaire de la famille des thienopyridines sous forme de base.
WO2010009745A1 (en) * 2008-07-25 2010-01-28 Pharmathen S.A. Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof
WO2010041276A1 (en) * 2008-10-06 2010-04-15 Jubilant Organosys Limited Pharmaceutical compositions comprising amorphous esomeprazole, dosage forms and process thereof
CZ2008748A3 (cs) * 2008-11-26 2010-06-02 Zentiva, A. S Zpusob výroby vysoce cistého 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c] pyridin-2-yl acetátu, prasugrelu
AU2010259003A1 (en) * 2009-06-08 2011-11-10 Merck Sharp & Dohme Corp. A thrombin receptor antagonist and clopidogrel fixed dose tablet
CN101695496A (zh) * 2009-10-15 2010-04-21 苏春华 一种含有三氟柳和氯吡格雷的药物组合物
JP2013032289A (ja) * 2009-10-28 2013-02-14 Daiichi Sankyo Co Ltd ワックス安定製剤
HU229035B1 (en) 2009-12-21 2013-07-29 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing prasurgel
HU229031B1 (en) 2009-12-21 2013-07-29 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing prasurgel and its intermediate
EP2275087B8 (en) * 2010-02-22 2012-11-21 Jrs Pharma GmbH+Co.kG Prasugrel controlled release formulations
CN102232949A (zh) * 2010-04-27 2011-11-09 孙远 提高药物溶出度的组合物及其制备方法
JP2012008044A (ja) * 2010-06-25 2012-01-12 Yamaguchi Univ 血小板活性化能の測定方法および抗血小板薬の評価方法
HUP1000565A2 (en) 2010-10-22 2012-05-02 Egis Gyogyszergyar Nyrt Process for the preparation of pharmaceutically active compound and intermediers
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
CN103781478A (zh) * 2011-06-24 2014-05-07 艾森达制药有限公司 用以改善酯类前药吸收率的方法与改良的药学组合物
CA2848756A1 (en) * 2011-09-14 2013-03-21 Pozen Inc. Phased dosing of clopidogrel
EA029341B1 (ru) * 2011-09-14 2018-03-30 Поузен Инк. Способы предоставления антитромбоцитарной терапии
CN102406938A (zh) * 2011-11-29 2012-04-11 北京阜康仁生物制药科技有限公司 一种抗血栓的药物组合物
CN106860398A (zh) * 2015-12-13 2017-06-20 北京蓝丹医药科技有限公司 一种高生物利用度的氯吡格雷药物组合物
HU231079B1 (hu) 2016-06-23 2020-06-29 Richter Gedeon Nyrt. Eljárás nagytisztaságú Prasugrel előállítására bromopentil szennyezés eltávolításával
JOP20190198A1 (ar) * 2018-08-28 2020-02-28 Hk Inno N Corp تركيبة صيدلانية تشتمل على عامل مضاد للصفيحات ومثبط إفراز حمض معدي
EP3939585A4 (en) * 2020-05-20 2022-03-02 Syntekabio, Inc. PREVENTIVE OR THERAPEUTIC COMPOSITION FOR INFECTIOUS DISEASES WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2
KR20240050841A (ko) * 2022-10-12 2024-04-19 일양약품주식회사 클로피도그렐 및 일라프라졸을 포함하는 복합제제

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136145A (en) 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
FR2530247B1 (fr) 1982-07-13 1986-05-16 Sanofi Sa Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique
US4464372A (en) 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4713243A (en) 1986-06-16 1987-12-15 Johnson & Johnson Products, Inc. Bioadhesive extruded film for intra-oral drug delivery and process
US4833149A (en) 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
JPH0645536B2 (ja) 1989-01-31 1994-06-15 日東電工株式会社 口腔粘膜貼付剤および口腔粘膜貼付製剤
US5041442A (en) 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
US5635477A (en) 1991-09-30 1997-06-03 The Dupont Merck Pharmaceutical Company Cyclic compounds useful as inhibitors of platelet glycoprotein IIB/IIIA
AU7568394A (en) 1993-08-19 1995-03-14 Cygnus Therapeutic Systems Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity
CA2173506C (en) 1993-10-12 2006-05-09 Tomohisa Matsushita Enteric granule-containing tablets
US5576328A (en) * 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
UA41946C2 (uk) 1994-07-08 2001-10-15 Астра Актієболаг Оральна фармацевтична складова одинична дозована форма у вигляді таблетки, спосіб її одержання, упаковка у вигляді блістера та спосіб інгібування секреції шлункової кислоти і/або лікування шлунково-кишкових запальних захворювань
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
AU3343295A (en) 1994-08-12 1996-03-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridine salt
RU2129549C1 (ru) 1994-08-13 1999-04-27 Юхан Корпорейшн Производные пиримидина и способы их получения
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6252076B1 (en) 1996-05-04 2001-06-26 Yuhan Corporation Process for preparation of pyrimidine derivatives
ATE206117T1 (de) 1996-05-04 2001-10-15 Yuhan Corp Verfahren zur herstellung von pyrimidin-derivaten
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
WO1998018784A1 (en) 1996-10-29 1998-05-07 Yuhan Corporation Process for preparation of pyrimidine derivatives
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
JP2002502421A (ja) * 1997-06-05 2002-01-22 イーライ・リリー・アンド・カンパニー 血栓障害の処置方法
ZA987800B (en) 1997-08-27 1999-06-09 Hexal Ag Pharmaceutical composition of meloxicam
ATE252892T1 (de) 1997-09-11 2003-11-15 Nycomed Danmark Aps Aus mehreren einzeleinheiten zusammengesetzte arzneimittel mit nicht-steroidalen wirkstoffen (nsaids)
US6296876B1 (en) 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2774288B1 (fr) 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US6184220B1 (en) 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
CA2241342C (en) 1998-06-15 2000-02-08 Bernard Charles Sherman Pharmaceutical tablets comprising an nsaid and a prostaglandin
US6365182B1 (en) 1998-08-12 2002-04-02 Cima Labs Inc. Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
FR2784583B1 (fr) 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
AU2001267916B2 (en) 2000-07-06 2004-09-09 Daiichi Sankyo Company, Limited Hydropyridine derivative acid addition salts
AU2001271055B2 (en) 2000-07-17 2005-07-07 Astellas Pharma Inc. Pharmaceutical composition improved in peroral absorbability
US6544556B1 (en) * 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
US20020131990A1 (en) 2000-11-30 2002-09-19 Barkalow David G. Pullulan free edible film compositions and methods of making the same
US6692771B2 (en) 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
PT1411900E (pt) 2001-06-01 2010-10-11 Pozen Inc Composições farmacêuticas para a entrega coordenada de aines
US6656493B2 (en) 2001-07-30 2003-12-02 Wm. Wrigley Jr. Company Edible film formulations containing maltodextrin
US6419903B1 (en) 2001-08-20 2002-07-16 Colgate Palmolive Company Breath freshening film
US6930099B2 (en) 2001-09-07 2005-08-16 Advanced Medical Instruments Composition for the treatment and prevention of endothelial dysfunction
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US20040247649A1 (en) 2002-02-11 2004-12-09 Edizone, Lc Medicine-containing orally soluble films
US7014862B2 (en) 2002-05-20 2006-03-21 The Procter & Gamble Company Chewable compositions containing a gel-forming extract of psyllium
US6599539B1 (en) 2002-07-31 2003-07-29 Poulenger Usa Inc. Perilla seed pesticide
US6824829B2 (en) 2002-08-23 2004-11-30 Acupac Packaging, Inc. Process for manufacturing thin film strips
AU2003270861A1 (en) * 2002-10-02 2004-04-23 Bristol-Myers Squibb Company Novel combination of a factor xa inhibitor and clopidogrel
AU2003297752A1 (en) 2002-12-06 2004-06-30 Monosolrx Llc Thin film delivery systems for volatile decongestants
US20040151756A1 (en) 2003-02-04 2004-08-05 Richards Anthony P. Edible low density high surface area drug vehicle, method of manufacturing low density high surface area drug vehicle
US20050075432A1 (en) 2003-10-07 2005-04-07 Verrall Andrew P. Acidulent film and method of making same
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
US20050196355A1 (en) 2004-03-03 2005-09-08 Constantine Georgiades Film products having controlled disintegration properties
US20060177504A1 (en) 2005-02-08 2006-08-10 Renjit Sundharadas Combination pain medication
US9532945B2 (en) 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
MX2008012514A (es) 2006-04-04 2009-02-10 Cogentus Pharmaceuticals Inc Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de acido.

Also Published As

Publication number Publication date
TR201816133T4 (tr) 2018-11-21
SI2007362T1 (sl) 2018-12-31
WO2007115305A3 (en) 2008-04-24
EP2007362A4 (en) 2012-11-28
WO2007115305A2 (en) 2007-10-11
PT2007362T (pt) 2018-12-12
AU2007234398B2 (en) 2013-05-23
CN101460154A (zh) 2009-06-17
JP5844028B2 (ja) 2016-01-13
EP2007362A2 (en) 2008-12-31
KR20150105419A (ko) 2015-09-16
CA2647497C (en) 2016-01-12
RS58162B1 (sr) 2019-03-29
KR20080112361A (ko) 2008-12-24
CY1120961T1 (el) 2019-12-11
HUE040311T2 (hu) 2019-02-28
HRP20181971T1 (hr) 2019-02-08
CN101460154B (zh) 2015-07-01
LT2007362T (lt) 2018-11-26
ES2699444T3 (es) 2019-02-11
MX349787B (es) 2017-08-11
KR101784001B1 (ko) 2017-10-23
MX2008012514A (es) 2009-02-10
IL194472A (en) 2016-02-29
US9504678B2 (en) 2016-11-29
CA2647497A1 (en) 2007-10-11
IL194472A0 (en) 2009-08-03
EP2007362B1 (en) 2018-09-05
PL2007362T3 (pl) 2019-02-28
JP2013256525A (ja) 2013-12-26
AU2007234398A1 (en) 2007-10-11
US20070243243A1 (en) 2007-10-18
SG170826A1 (en) 2011-05-30
HK1131566A1 (en) 2010-01-29
JP2009532500A (ja) 2009-09-10
JP2016028098A (ja) 2016-02-25
BRPI0709745A2 (pt) 2011-07-26
AU2007234398B9 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
DK2007362T3 (da) Orale doseringsformer, herunder et antitrombocytmiddel og en syrehæmmer
US9532945B2 (en) Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
US9636306B2 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
ES2208775T3 (es) Formas de dosificacion efervescentes de multiples unidades que comprenden inhibidor de la bomba de protones.
US20070154542A1 (en) Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
CA2753444A1 (en) Controlled-release compositions comprising a proton pump inhibitor
NO316863B1 (no) Oral farmasoytisk, tablettert multippel enhetsdoseringsfom, fremgangsmate for dens fremstilling, anvendelse derav, og blaerepakning
CA2592542A1 (en) Dosage form for treating gastrointestinal disorders
KR20110104124A (ko) 판토프라졸을 활성 성분으로서 함유하는 제형
US20090214599A1 (en) Proton pump inhibitor formulations, and methods of preparing and using such formulations
CA2740974A1 (en) Dosage forms for the rapid and sustained elevation of gastric ph
US20110293713A1 (en) Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs
CA2871221A1 (en) Delayed release pharmaceutical compositions of salsalate
KR20230079406A (ko) 장용성 펠렛, 이의 제조 방법 및 이를 포함하는 제제